April 2024

The independent Data and Safety Monitoring Board (DSMB) recommended the continuation of patient enrollment as planned.There has been no safety concern with the use of Leuprolide (FP-001) injectable Emulsion in pediatric CPP patients. TAIPEI, April 1, 2024 /PRNewswire/ — Foresee Pharmaceutical

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: